This study provides proof-of-concept for an approach to DCM therapy based upon targeting mAKAPβ-PP2A signalosomes that is expected to be etiologic independent and may be applicable regardless of DCM mutation. The gene discussed is PTPA; the disease is familial dilated cardiomyopathy.